查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018815

自体免疫疾病体外诊断与实验室自建检测市场：2026年至2032年全球市场预测（按检测类型、技术、产品类型、检体类型、最终用户和应用划分）

IVD & LDT For Autoimmune Diseases Market by Test Type, Technology, Product Type, Sample Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，自体免疫疾病的体外诊断和实验室自建市场价值将达到 192.6 亿美元，到 2026 年将成长至 202.8 亿美元，到 2032 年将达到 275.6 亿美元，年复合成长率为 5.25%。

主要市场统计数据
基准年 2025 192.6亿美元
预计年份：2026年 202.8亿美元
预测年份 2032 275.6亿美元
复合年增长率 (%) 5.25%

对当前自体免疫疾病诊断现状进行简要概述，重点关注诊断方法的创新、临床应用的驱动因素以及对相关人员的战略意义。

诊断技术的创新、不断演进的临床路径以及临床医生对自体免疫疾病检测准确性日益增长的需求，共同为诊断和检测服务领域的相关人员创造了一个关键的转折点。本执行摘要概述了检测平台、临床医生采纳模式以及体外诊断与实验室自建检测 (LDT) 之间相互作用的最新趋势，这些因素共同塑造了诊断工作流程和患者护理过程。报告重点关注技术选择、监管政策调整和检查室运作模式如何影响检测方法的选择、分析性能以及后续的护理协调。

检测技术创新、监管趋势和临床工作流程现代化的整合正在重塑自体免疫疾病的诊断，并加速跨部门合作。

近年来，变革性的变化从根本上改变了自体免疫疾病诊断的开发、检验和临床应用方式。检测化学和平台整合技术的进步提高了分析精度，多重检测能力使得从单一检体中获得更广泛的免疫谱分析成为可能。同时，检查室正在采用自动化和数位化连接来简化工作流程并支援高通量检测，这反过来又影响了报告时间和检测能力管理。

本研究评估了 2025 年关税调整对诊断供应链、筹资策略和区域製造决策的累积营运影响。

2025年实施的关税政策调整及相关贸易措施为全球诊断试剂和仪器组件供应链带来了新的波动。这些关税趋势增加了製造商和检查室的采购复杂性，促使他们重新评估筹资策略、库存管理和供应商多元化。为此，许多相关人员探索了近岸外包方案和建立替代供应商关係，以减轻进口成本波动和前置作业时间不确定性的影响。

详细的細項分析揭示了测试类型、检测技术、产品类型、最终用户、临床应用和检体方式如何影响策略选择。

細項分析揭示了不同检测类型、技术、产品类型、最终用户、应用和检体类型之间的不同趋势，这些趋势影响着临床效用、采购选择和开发重点。按检测类型划分，这些趋势包括抗环瓜氨酸肽抗体、抗核抗体、乳糜泻和类风湿因子，每种检测都有其独特的分析要求和临床医生对特异性和可解释性的期望。由于抗环瓜氨酸肽抗体 (ACCP) 检测具有有用的预后分析特性，因此通常是类风湿性关节炎早期诊断的首选方法。另一方面，抗核抗体 (ANA) 检测通常用作筛检工具，需要反射性演算法来指导后续检测。乳糜泻的血清学检测需要与病历和基因检测途径密切配合，而类风湿因子检测作为更广泛的发炎性疾病评估的一部分仍然具有重要价值。

关键地区不同的法规环境、支付方框架和临床基础设施如何决定诊断测试部署模式和策略市场进入？

区域趋势以独特的方式影响技术采纳模式、监管路径和商业性模式。在美洲，医疗保健系统涵盖了高度集中的国家级计画和公私混合模式，支付方的影响力显着影响报销路径和技术采纳率。关键市场的临床实践指南和专家网络推动了临床医生对特定自体免疫检测的需求，而大学附属医院通常主导转化检验，从而指南更广泛的临床应用。因此，与当地指南制定和支付方证据要求一致的推广策略往往能够加速技术采纳。

针对公司和检查室的策略方法，强调平台扩展、建立证据伙伴关係和业务规模化，以促进诊断可靠性和临床整合。

自体免疫诊断领域的企业策略体现了多元化的优先事项，包括平台创新、伙伴关係以及服务拓展，以满足临床需求和检查室偏好。主要企业正致力于扩展检测项目并提昇平台间的互通性，以满足检体检查室和高通量参考中心的需求。这些努力通常与和学术机构的策略合作相结合，以检验新型生物标誌物，并产生纳入指南和获得支付方审核所需的临床证据。

为诊断和实验室领导者提供可操作的策略重点，以加强证据、增强韧性并加快所有护理路径中的临床实施。

行业领导者应采取协作策略，协调检测开发、证据生成和检查室运营，以加速临床应用并改善患者预后。首先，应优先进行临床检验项目，以证明其在真实患者群体中具有实际效用，并确保研究设计能够反映临床医生的决策要点和支付方的证据要求。同时，应投资于互通性和工作流程整合，确保检测能够无缝整合到实验室资讯系统和电子健康记录中，从而最大限度地减轻申请检测的临床医生和检查室工作人员的负担。

透过透明、多方面的调查方法，结合专家访谈、指南整合和可复製的分析框架，我们得出实用的诊断见解。

本研究整合了多种资料来源、结构化访谈和透明的分析框架，以确保得出可靠且可重复的结论。关键的定性资料包括对临床实验室管理人员、检测开发人员、监管专家和自体免疫疾病临床医生的访谈，这些访谈提供了关于检验实践、推广障碍以及影响临床决策因素的实用见解。这些访谈构成了主题分析的基础，并指导了案例研究的选择，这些案例研究展示了检测方法在诊断过程中的实际应用。

结论：透过协调创新、证据生成和运作韧性，推动自体免疫疾病诊断的实质改善。

最后，自体免疫疾病诊断领域正处于一个转折点，其特点是分析性能要求不断提高、证据生成与临床效用之间的联繫日益紧密，以及受供应链现实驱动的更为严格的运营审查。整合严格检验、无缝工作流程相容性和稳健筹资策略的相关人员将更有能力将技术进步转化为实际的临床影响。体外诊断和实验室自建检测方法之间的互动提供了两个切实可行的途径，使标准化和灵活性能够并存，从而满足多样化的临床需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：自体免疫疾病体外诊断与实验室自建市场－依检测类型划分

  • 抗环瓜氨酸肽
  • 抗核抗体
  • 乳糜泻
  • 类风湿因子

第九章：自体免疫疾病体外诊断与实验室自建市场：依技术划分

  • 化学冷光免疫检测
  • 酵素免疫分析法
  • 萤光免疫分析
  • 多重免疫检测

第十章：自体免疫疾病体外诊断与实验室自建市场：依产品类型划分

  • 体外诊断试剂
  • 实验室开发的测试

第十一章自体免疫疾病的体外诊断与实验室自建市场—检体类型

  • 干血斑
  • 电浆
  • 血清
  • 全血

第十二章：自体免疫疾病的体外诊断和实验室自建市场：按最终用户划分

  • 学术研究机构
  • 诊断检查室
  • 医院检查室
  • 标准检验组织

第十三章：自体免疫疾病的体外诊断与实验室自建市场：按应用领域划分

  • 乳糜泻
  • 多发性硬化症
  • 类风湿性关节炎
  • 全身性红斑性狼疮
  • 1型糖尿病

第十四章：自体免疫疾病体外诊断与实验室自建市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：自体免疫疾病体外诊断与实验室自建市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：自体免疫疾病体外诊断与实验室自建市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国自体免疫疾病的体外诊断与实验室自建市场

第十八章：中国自体免疫疾病体外诊断与实验室自建市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies Inc.
  • Atlas Link Technology Co., Ltd
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • Corgenix, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • EUROIMMUN AG
  • F. Hoffmann-La Roche Ltd.
  • Grifols, SA
  • Hologic Inc.
  • ImmunoScience India Pvt. Ltd.
  • Ortho Clinical Diagnostics, Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics, Inc.
  • Quidel Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
Product Code: MRR-ED54C46E8807

The IVD & LDT For Autoimmune Diseases Market was valued at USD 19.26 billion in 2025 and is projected to grow to USD 20.28 billion in 2026, with a CAGR of 5.25%, reaching USD 27.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.26 billion
Estimated Year [2026] USD 20.28 billion
Forecast Year [2032] USD 27.56 billion
CAGR (%) 5.25%

A concise orientation to the current autoimmune diagnostics environment highlighting assay innovation, clinical adoption drivers, and strategic implications for stakeholders

The convergence of diagnostic innovation, evolving clinical pathways, and growing clinician demand for precision in autoimmune disease detection has created a pivotal moment for stakeholders across diagnostics and laboratory services. This executive summary distills recent advances in assay platforms, clinician adoption patterns, and the interplay between in vitro diagnostics and lab-developed tests that together shape diagnostic workflows and patient journeys. It centers on how technological choices, regulatory clarity, and laboratory operational models influence test selection, analytical performance, and downstream care coordination.

As diagnostics teams and laboratory leaders evaluate next-generation assay adoption, they must balance analytical sensitivity and specificity with workflow integration and reimbursement realities. Laboratory directors increasingly prioritize assays that reduce turnaround time while preserving clinical confidence, and clinicians seek tests that support earlier, more definitive diagnoses. Meanwhile, manufacturers refine product portfolios to address unmet needs in serology and biomarker detection, and academic centers expand translational programs to validate novel targets.

Taken together, these dynamics underscore the importance of aligning product development, clinical validation, and commercialization strategies. This summary outlines the strategic considerations that leaders should weigh when designing evidence generation plans, optimizing laboratory operations, and engaging payers and clinicians to improve diagnostic impact and patient outcomes.

How converging assay innovations, regulatory dynamics, and clinical workflow modernization are reshaping autoimmune diagnostics and accelerating cross-sector collaboration

Recent transformative shifts have altered how autoimmune disease diagnostics are developed, validated, and adopted across clinical settings. Advances in assay chemistries and platform integration have improved analytical precision, while multiplexing capabilities enable broader immunoprofiling from single samples. In parallel, laboratories are embracing automation and digital connectivity to streamline workflows and support high-throughput testing, which in turn affects turnaround times and capacity management.

Regulatory and reimbursement landscapes have also evolved, prompting manufacturers and laboratories to accelerate robust clinical validation and real-world evidence generation. These trends favor tests that demonstrate actionable clinical utility and that fit into clinicians' decision-making pathways. The rise of lab-developed tests alongside commercial in vitro diagnostics has created a complementary ecosystem: LDTs often address niche or emergent clinical needs quickly, while commercial IVDs prioritize standardization and scalability. Consequently, strategic partnerships between clinical laboratories, academic research centers, and commercial manufacturers have grown more common, facilitating faster translation of biomarkers into validated testing options.

Furthermore, patient-centric care models and increased clinician awareness of autoimmune heterogeneity emphasize the need for more precise diagnostic algorithms. As a result, stakeholders are investing in clinician education, multidisciplinary diagnostic protocols, and integrated reporting that links serologic results to clinical phenotypes. Overall, these shifts are driving a more collaborative, data-driven approach to autoimmune diagnostics, where technological capability, evidence generation, and operational readiness intersect to determine clinical adoption.

Assessing the cumulative operational consequences of 2025 tariff adjustments on diagnostic supply chains, sourcing strategies, and regional manufacturing decisions

Tariff policy adjustments and related trade measures introduced in 2025 have introduced new variables into global supply chains for diagnostic reagents and instrument components. These tariff developments increased procurement complexity for manufacturers and laboratories, prompting reassessments of sourcing strategies, inventory management, and supplier diversification. In response, many stakeholders examined nearshoring options and alternative supplier relationships to mitigate exposure to variable import costs and lead-time uncertainties.

Supply chain reactions to tariff changes encouraged manufacturers to revisit bill-of-materials strategies and to prioritize modular instrument designs that allow substitution of nonproprietary parts. Simultaneously, diagnostic laboratories adjusted procurement windows, increasing buffer inventories for critical consumables and negotiating longer-term agreements with domestic or regional distributors when feasible. These operational shifts, while preserving testing continuity, placed a premium on supply chain visibility and proactive supplier risk assessments.

Moreover, the tariff environment catalyzed strategic conversations about manufacturing footprint and regional capacity. Some firms accelerated investments in regional manufacturing and final assembly capabilities to reduce cross-border exposure, while others amplified their focus on validating multiple reagent suppliers to ensure continuity. Collectively, these adaptations underscore the critical link between trade policy and diagnostic program resilience, highlighting the need for scenario planning and agile procurement practices to sustain testing access and laboratory operations.

Detailed segmentation insights revealing how test types, assay technologies, product categories, end users, clinical applications, and sample modalities influence strategic choices

Segmentation analysis reveals differentiated dynamics across test types, technologies, product categories, end users, applications, and sample types that influence clinical utility, procurement choices, and development priorities. Based on Test Type, the landscape includes Anti Cyclic Citrullinated Peptide, Antinuclear Antibody, Celiac Disease, and Rheumatoid Factor, each presenting unique analytical requirements and clinician expectations for specificity and interpretability. Anti Cyclic Citrullinated Peptide assays are commonly prioritized for early rheumatoid arthritis diagnosis because their analytical characteristics support prognostic use, whereas Antinuclear Antibody testing often serves as a screening tool requiring reflex algorithms to guide follow-up testing. Celiac Disease serology necessitates tight integration with clinical history and genetic testing pathways, and Rheumatoid Factor testing retains value as part of broader inflammatory workups.

Based on Technology, stakeholders evaluate platforms including Chemiluminescence Immunoassay, Enzyme Linked Immunosorbent Assay, Fluorescence Immunoassay, and Multiplex Immunoassay when balancing throughput, sensitivity, and cost. Chemiluminescence Immunoassay platforms often appeal to high-volume laboratories seeking automated workflows and consistent performance, while Enzyme Linked Immunosorbent Assay remains a flexible option for lower throughput and centralized reference testing. Fluorescence Immunoassay can offer enhanced sensitivity for specific analytes, and Multiplex Immunoassay enables simultaneous profiling that supports differential diagnosis and research-grade immunophenotyping.

Based on Product Type, distinctions between In Vitro Diagnostic and Lab Developed Test pathways shape validation rigor, regulatory interaction, and commercial strategy. In Vitro Diagnostic solutions emphasize standardized kits and instrument integration to facilitate broad adoption, whereas Lab Developed Tests provide customization and rapid responsiveness to evolving clinical needs, especially in specialized centers. Based on End User, academic and research institutes, diagnostic laboratories, hospital laboratories, and reference laboratories each maintain different priorities related to validation depth, throughput, clinical integration, and payer relationships; academic centers drive translational validation, hospital laboratories focus on clinician alignment and rapid turnaround, and reference laboratories emphasize scale and centralized expertise.

Based on Application, reporting for Celiac Disease, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Type 1 Diabetes demands tailored panels and interpretive frameworks that reflect disease-specific biomarker signatures and clinical algorithms. Clinicians increasingly expect tests to provide context-rich reports that integrate serologic patterns with likelihood assessments and recommended next steps. Finally, based on Sample Type, modalities such as Dried Blood Spot, Plasma, Serum, and Whole Blood affect collection logistics, stability considerations, and suitability for decentralized testing or remote sampling programs. Dried Blood Spot sampling supports outreach and decentralized screening initiatives, while plasma and serum remain predominant for high-sensitivity assays performed in centralized laboratories. These segmentation insights collectively inform product development priorities, clinical validation strategies, and commercialization approaches across the diagnostic ecosystem.

How distinct regulatory environments, payer frameworks, and clinical infrastructures across major regions determine diagnostic adoption patterns and strategic market entry

Regional dynamics shape adoption patterns, regulatory pathways, and commercial approaches in distinctive ways. Across the Americas, health systems vary from highly centralized national programs to mixed public-private models, and payer influence strongly shapes test reimbursement pathways and adoption velocity. Clinical practice guidelines and specialist networks in major markets drive clinician demand for specific autoimmune assays, and academic medical centers often lead translational validation that informs broader clinical adoption. Consequently, engagement strategies that align with local guideline development and payer evidence requirements tend to facilitate uptake.

In Europe, Middle East & Africa, the regulatory environment is heterogeneous, with some regions emphasizing centralized regulatory reviews and others maintaining national approval pathways. This diversity encourages modular regulatory and market entry strategies, alongside targeted clinical studies that address country-specific clinical practice patterns. Additionally, public health priorities and variable laboratory infrastructure across the region influence the feasibility of decentralized testing and the adoption of automated platforms versus reference lab models. Manufacturers and laboratories therefore balance regional evidence generation with flexible distribution partnerships.

Asia-Pacific markets demonstrate rapid uptake of innovative diagnostic technologies, supported by investments in clinical research infrastructures and expanding private laboratory networks. Diverse healthcare financing models and large patient populations create opportunities for both centralized reference testing and point-of-care initiatives, particularly when supported by remote-sampling approaches like Dried Blood Spot. Overall, regional strategies must account for regulatory complexity, payer frameworks, and local clinical practice to optimize adoption and align evidence generation with stakeholder expectations.

Strategic corporate and laboratory approaches highlighting platform expansion, evidence partnerships, and operational scaling that drive diagnostic credibility and clinical integration

Company strategies in autoimmune diagnostics reflect divergent priorities including platform innovation, partnerships, and service expansion to capture clinical demand and laboratory preference. Leading assay developers focus on expanding assay menus and enhancing platform interoperability to meet the needs of hospital laboratories and high-volume reference centers. These efforts often pair with strategic collaborations with academic institutions to validate novel biomarkers and to generate the clinical evidence necessary for guideline inclusion and payer consideration.

Laboratory groups and diagnostics service providers invest in expanding their LDT capabilities and in establishing centers of excellence for autoimmune testing, enabling rapid deployment of new assays and supporting clinician education. At the same time, developers of multiplex technologies emphasize the value proposition of comprehensive immunoprofiling for complex autoimmune presentations, targeting neurology and rheumatology centers that require broader serologic views for differential diagnosis. Mergers, acquisitions, and co-development agreements increasingly serve as mechanisms to accelerate entry into adjacent clinical segments and to access distribution networks in key regions.

Across commercial and laboratory stakeholders, there is a shared emphasis on evidence generation, interoperability, and scalable operations. Consequently, corporate investments prioritize clinical validation studies, real-world evidence programs, and post-market surveillance that demonstrate test performance in diverse patient cohorts. This focus enables companies and laboratories to align product positioning with clinician needs, regulatory expectations, and payer requirements, reinforcing diagnostic credibility and facilitating integration into care pathways.

Actionable strategic priorities for diagnostics and laboratory leaders to strengthen evidence, enhance resilience, and accelerate clinical adoption across care pathways

Industry leaders should adopt coordinated strategies that align assay development, evidence generation, and laboratory operations to accelerate clinical adoption and improve patient outcomes. First, prioritize clinical validation programs that demonstrate actionable utility in real-world patient cohorts, ensuring that study designs reflect clinician decision points and payer evidence needs. Simultaneously, invest in interoperability and workflow integration so that assays fit seamlessly into laboratory information systems and electronic health records, thereby minimizing friction for ordering clinicians and laboratory staff.

Second, diversify supply chains and consider regional manufacturing or final assembly to reduce exposure to trade-related disruptions. Building validated dual-source options for critical reagents and components will enhance operational resilience and support sustained testing capacity. Third, develop targeted engagement plans for key end users-academic centers for translational validation, hospital laboratories for operational fit, and reference laboratories for scale. These plans should include clinician education, interpretive reporting templates, and collaborative pilot programs that demonstrate clinical value.

Fourth, pursue partnerships to expand multiplexing capabilities and to develop integrated diagnostic algorithms that combine serologic results with clinical decision support. Finally, incorporate patient-centric sampling approaches, such as dried blood spot programs, to broaden access and to support decentralized testing initiatives. By implementing these recommendations, stakeholders can strengthen their competitive positioning while delivering diagnostics that align with evolving clinical workflows and patient care models.

A transparent, multi-source research methodology combining expert interviews, guideline synthesis, and reproducible analytical frameworks to generate actionable diagnostic insights

This research synthesizes multiple data sources, structured interviews, and a transparent analytical framework to ensure robust, reproducible findings. Primary qualitative inputs include interviews with clinical laboratory directors, assay developers, regulatory affairs specialists, and clinicians who treat autoimmune diseases, providing practical insights into validation practices, adoption barriers, and clinical decision drivers. These interviews informed thematic analysis and guided the selection of case studies that illustrate real-world integration of assays into diagnostic pathways.

Secondary inputs comprised peer-reviewed literature, clinical practice guidelines, and regulatory documentation that clarify analytic requirements and evidence expectations for both in vitro diagnostics and lab-developed tests. The methodological approach balanced depth and breadth by triangulating qualitative inputs with technical performance characteristics reported in the literature, paying particular attention to assay-specific validation metrics and sample type considerations. Data synthesis emphasized reproducibility, with cross-validation steps to reconcile discrepancies across sources and to ensure that interpretive claims reflect consensus where possible.

Analytical techniques included comparative validation mapping across technologies and test types, scenario-based supply chain impact assessment, and segmentation-driven insight generation to highlight actionable priorities for developers and laboratories. Throughout, we maintained clear documentation of assumptions and methodological choices, enabling clients to evaluate the applicability of findings to specific programs or geographies.

Concluding perspective on aligning innovation, evidence generation, and operational resilience to drive meaningful improvements in autoimmune disease diagnosis

In closing, the autoimmune diagnostics field stands at an inflection point characterized by higher expectations for analytical performance, tighter alignment between evidence generation and clinical utility, and greater operational scrutiny driven by supply chain realities. Stakeholders who integrate rigorous validation, seamless workflow compatibility, and resilient procurement strategies will be best positioned to translate technological advances into tangible clinical impact. The interplay of in vitro diagnostics and lab-developed tests offers a pragmatic dual-pathway where standardization and agility coexist to meet diverse clinical needs.

Leaders should focus on generating the right kinds of evidence to satisfy clinicians and payers, while investing in interoperability and interpretive reporting to enhance clinical utility. At the same time, supply chain diversification and regional capacity planning will remain critical to ensuring continuity of testing services. Taken together, these priorities suggest a roadmap where innovation, evidence, and operations align to support earlier and more accurate diagnosis, improved patient management, and more efficient laboratory workflows. Stakeholders who act decisively to address these areas will drive adoption and deliver value to clinicians, patients, and healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. IVD & LDT For Autoimmune Diseases Market, by Test Type

  • 8.1. Anti Cyclic Citrullinated Peptide
  • 8.2. Antinuclear Antibody
  • 8.3. Celiac Disease
  • 8.4. Rheumatoid Factor

9. IVD & LDT For Autoimmune Diseases Market, by Technology

  • 9.1. Chemiluminescence Immunoassay
  • 9.2. Enzyme Linked Immunosorbent Assay
  • 9.3. Fluorescence Immunoassay
  • 9.4. Multiplex Immunoassay

10. IVD & LDT For Autoimmune Diseases Market, by Product Type

  • 10.1. In Vitro Diagnostic
  • 10.2. Lab Developed Test

11. IVD & LDT For Autoimmune Diseases Market, by Sample Type

  • 11.1. Dried Blood Spot
  • 11.2. Plasma
  • 11.3. Serum
  • 11.4. Whole Blood

12. IVD & LDT For Autoimmune Diseases Market, by End User

  • 12.1. Academic And Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospital Laboratories
  • 12.4. Reference Laboratories

13. IVD & LDT For Autoimmune Diseases Market, by Application

  • 13.1. Celiac Disease
  • 13.2. Multiple Sclerosis
  • 13.3. Rheumatoid Arthritis
  • 13.4. Systemic Lupus Erythematosus
  • 13.5. Type 1 Diabetes

14. IVD & LDT For Autoimmune Diseases Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. IVD & LDT For Autoimmune Diseases Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. IVD & LDT For Autoimmune Diseases Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States IVD & LDT For Autoimmune Diseases Market

18. China IVD & LDT For Autoimmune Diseases Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Adaptive Biotechnologies Corporation
  • 19.7. Agilent Technologies Inc.
  • 19.8. Atlas Link Technology Co., Ltd
  • 19.9. Becton, Dickinson and Company
  • 19.10. Bio-Rad Laboratories Inc.
  • 19.11. bioMerieux SA
  • 19.12. Corgenix, Inc.
  • 19.13. Danaher Corporation
  • 19.14. DiaSorin S.p.A.
  • 19.15. EUROIMMUN AG
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. Grifols, S.A.
  • 19.18. Hologic Inc.
  • 19.19. ImmunoScience India Pvt. Ltd.
  • 19.20. Ortho Clinical Diagnostics, Inc.
  • 19.21. PerkinElmer, Inc.
  • 19.22. Quest Diagnostics, Inc.
  • 19.23. Quidel Corporation
  • 19.24. Siemens Healthineers AG
  • 19.25. Sysmex Corporation
  • 19.26. Thermo Fisher Scientific Inc.
  • 19.27. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)